Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y6V7

UPID:
DDX49_HUMAN

ALTERNATIVE NAMES:
DEAD box protein 49

ALTERNATIVE UPACC:
Q9Y6V7; E7ENA0; Q53FJ1; Q9BVQ8

BACKGROUND:
DEAD box protein 49, recognized as Probable ATP-dependent RNA helicase DDX49, is integral to RNA metabolic processes. It functions to modify RNA structure, playing a pivotal role in essential cellular processes such as RNA splicing and ribosome assembly, through its ATP-driven helicase activity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of DEAD box protein 49 offers a pathway to novel therapeutic approaches. Given its critical role in RNA metabolism, targeting DDX49 could provide new avenues for treating conditions associated with RNA dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.